BACKGROUND AND PURPOSE: Stent-supported aneurysm coiling has been utilized with increasing frequency over the past few years, particularly for addressing treatment of complex and wide-neck aneurysms. A sizable body of literature describing various experiences with stent-supported coiling now exists. The purpose of this research was to carry out a comprehensive literature survey of stent-supported aneurysm coiling.
ndovascular treatment of cerebral aneurysms with detachable coils has become increasingly adopted over the past 2 decades. The widespread acceptance of endosaccular coiling however has been dampened by the likelihood of aneurysm recurrence concerns over the durability of treatment and the significance of incompletely treated aneurysms. 1 These issues are, ironically, most relevant to the subgroup of complex and large aneurysms for which coiling was initially used. Yet another group of fusiform and wide-neck aneurysms remained unaddressed by reconstructive surgical and endovascular techniques until the introduction of dedicated intracranial stentlike devices, such as Neuroform (Boston Scientific, Natick, Massachusetts), Enterprise (Cordis, Miami Lakes, Florida), Solitaire (ev3, Irvine, California), and LEO (Balt Extrusion, Montmorency, France). Stent deployment across the aneurysm neck, followed immediately or in delayed manner, by coil packing of the aneurysm, has slowly been more widely adopted, particularly for complex aneurysms, with the intention to promote improved coil packing densities and greater stability of the coil mass within the aneurysmal sac; hypothetically reducing the likelihood of neck recurrence and coil compaction through some hemodynamic modification of aneurysmal blood flow and facilitation of intimal overgrowth of the implant and neck region coils. Although the availability of these devices has enabled the endovascular treatment of previously uncoilable and inoperable aneurysms, the use of stentassisted coiling has brought with it other important considerations, including the necessity of aggressive antiplatelet therapy that limits its application in the setting of subarachnoid hemorrhage, and delayed stent-related issues such as the development of in-stent stenosis and parent vessel occlusion.
The purpose of the present study was to review the literature on stent-assisted coiling to ascertain the frequency of stent-related complications and to assess the impact of the technique on the angiographic and anatomic outcome of endovascular aneurysm treatment.
Materials and Methods
Medline and PubMed searches were performed through January 2011 to identify relevant articles by using search strings of Neuroform, Enterprise, LEO, intracranial stent, aneurysm coiling rupture, aneurysm coiling thrombosis, cerebral stent, and intracranial aneurysm stent from 1999 to 2011. A Google search by using the string "intracranial aneurysm stent" also yielded several not otherwise identified articles. Additional sources were culled through bibliographies of existing articles. Information derived from discovered articles was used for overall procedure complication analysis and, when available, for specific long-term follow-up metrics. Articles selected for overall procedure analysis were required to contain information on the total number of subjects in the study and overall number of complications and procedure-related deaths. Additional information, available in most publications, was collected regarding the following: 1) type of complication encountered (eg, thromboembolic, hemorrhagic); 2) fraction of patients in whom the stent could not be delivered (considered as a stent-related technical complication) or where any issue was encountered with a deployed stent (eg, malposition, migration); and 3) aneurysm size, rupture status, location, and initial posttreatment occlusion.
Articles with fewer than 5 cases were excluded. Most papers fulfilling the above-mentioned criteria also contained information on some form of patient follow-up. In addition, some publications not meeting the above-mentioned criteria for overall treatment analysis were used exclusively for follow-up calculations and included clinical (length, incidence of death, or TIA/ stroke in the relevant brain territory) and imaging data (aneurysm occlusion, recanalization, retreatment, in-stent stenosis/occlusion).
In some instances, publications from an individual center or centers contained potentially duplicate patient data. A single publication providing the most comprehensive dataset was then selected.
Ten publications [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] contained data, usually in table format, on each patient within the study. In such cases, we collected information on total complications, stent complications, and death in the first 10 patients, and compared these parameters with those of subsequent patients in the same study for a "learning curve" analysis. For this component of the study, a meta-analysis was conducted to compare the first 10 subjects treated with subsequent patients in terms of the percentage of subjects manifesting overall complications, death, overall stent problems, stent delivery problems, or other stent problems. A separate analysis was conducted for each of these comparisons. Both random and fixed effects models were evaluated. Under the fixed effects model, it is assumed that all studies come from a common population and that the effect size, represented as an OR, is not different among the different studies. This assumption was tested by a heterogeneity test based on the Q statistic. If this test yields a significant result, then the fixed effects model may be invalid. In this case, the random effects model may be more appropriate, in which both the random variation within the studies and the variation between the different studies is incorporated. For the meta-analysis of each outcome measure, the comparison was based on the Mantel-Haenszel method for calculating the weighted summary OR under the fixed effects model. For each outcome measure, the heterogeneity statistic Q was then incorporated to calculate the summary OR under the random effects model. In the analysis for each outcome measure, only studies providing relevant data for both groups were included in the meta-analysis to avoid confounding of differences between studies with differences between groups. Statistical significance was defined as P Ͻ .05. MedCalc version 10.4.0.0 (Frank Schoonjans, Mariakerke, Belgium) was used for all computations.
No institutional review board clearance is required at our center for literature surveys.
Results

Overall Data
In total, 39 articles 2-40 with 1517 patients met inclusion criteria for overall treatment, follow-up analyses, or both. Thirtyseven of these articles, reporting on 1510 aneurysms in 1457 patients, contained data for both overall procedure and specific follow-up data analysis. Two articles 37, 38 were used exclusively for follow-up analysis. The results are provided in Online Table 1 . As evident from the table, only overall complication data were required to be present in every article. Additional parameters (eg, aneurysm size, initial occlusion) were not present in all publications. Calculations by using these parameters were carried out based on the number of subjects or cases within the relevant parameter dataset, and not on the overall subject or case number. Thus, the percentages listed in On-line Table 1 may not be deducible from overall figures provided in the table.
Complications
The overall complication incidence was 19%, with an overall death incidence of 2.1%. Thromboembolic issues were most prevalent at close to 10%, leading to death in 0.6% of overall cases. Hemorrhagic complications occurred in 2.2% of cases but carried a higher association with mortality, accounting for 0.9% of overall deaths. Coil-related technical issues were infrequent (2%) and almost always asymptomatic. Stent-Related Technical Complications. Overall, 9% of cases were associated with technical stent-related failure. Of these, the stent could not be deployed in 4%. The remaining 5% included various issues related to an already deployed stent, such as migration and premature or misplaced deployment.
Initial Occlusion
Approximately 45% of aneurysms were deemed completely occluded at immediate postprocedure angiography. Due to heterogeneity in outcome reporting, we found no consistent method of categorizing near-complete, subtotal, incomplete, or residual occlusions into a quantifiable entity.
Size
Overall, approximately 63% of aneurysms measured Ͻ10 mm in diameter. No stratification of initial or follow-up angiographic occlusion rate according to size was feasible.
Rupture Status
Twenty-two percent of aneurysms were treated in the setting of acute or relatively recent subarachnoid hemorrhage. No breakdown of complication incidence with respect to rupture status was possible.
Clinical Follow-Up
Twenty-seven papers [2] [3] [4] [5] 7, [9] [10] [11] 13, [15] [16] [17] [18] 20, 24, 25, [28] [29] [30] [33] [34] [35] [36] [37] [38] [39] [40] , containing 736 patients, reported clinical follow-up of 13-month average duration and 6-month median duration. Twenty-one patients (3.2%) suffered delayed TIA/stroke in the territory subserved by the stented vessel.
Imaging Follow-Up
Twenty-three articles [2] [3] [4] [5] 7, 9, 11, [15] [16] [17] [18] 24, 25, 30, [32] [33] [34] [35] [36] [37] [38] [39] [40] with 695 patients provided imaging (almost entirely catheter angiogrambased) follow-up data, reporting a 61% rate of complete aneurysm occlusion at variable follow-up times. Among these reports, 14% of aneurysms initially scored as completely occluded and subsequently recanalized, and 23% of aneurysms initially judged incompletely treated on the immediate posttreatment angiograms progressed to complete occlusion. Sixty-two patients (13%) underwent retreatment. In-stent stenosis was observed in 24 cases (3.5%) at an average 5 months of follow-up. Of these, 4 stenoses (17%) were symptomatic. Delayed parent vessel/stent occlusion was noted in 4 cases (0.6%, 3 asymptomatic, 1 stroke), at 8 months average follow-up.
Learning Curve Analysis
From the original dataset, 10 articles 2-11 provided information that allowed determination of complications, outcome, and stent delivery data for each individual patient within the study, enabling comparison of clinical and technical complication rates between early and late experiences. The results are listed in Table. Discussion We found a large heterogeneous body of literature describing stent-assisted coil embolization of cerebral aneurysms, consisting of mostly retrospective cases series. The heterogeneity in adverse outcome reporting was particularly evident, precluding accurate subdivision of adverse event categories into clinically useful entities such as permanent deficit or transient deficit, whereas mortality data were more consistently present.
Ideally, we would have liked to perform a statistical comparison of complication rates in stent-assisted coiling to that of "traditional" coiling. We have previously carried out a similar analysis by comparing balloon-assisted and traditional coiling. 41 However, such an analysis, to be statistically rigorous, requires that each publication contributing to the metaanalysis contain cases of both stent-assisted and traditional coiling treatment within the same study. To date, however, most publications reporting experience with stent-supported aneurysm treatment have no such "control" arm, precluding meaningful statistical analysis.
In a more qualitative sense, the overall complication rate of 19%, as determined by our analysis of predominantly unruptured aneurysm treatment, is somewhat higher than that reported by most large single-center series. 42, 43 This seems to stem mainly from a higher incidence of thromboembolism. Despite the perceived increased bleeding risk associated with dual antiplatelet use in stented patients, the prevalence of hemorrhagic complications was more comparable with those reported for traditional coiling of predominantly unruptured aneurysms. [41] [42] [43] A distinction among etiology of hemorrhage is also worthwhile in that traditional coiling is associated with predominantly subarachnoid hemorrhage due to periprocedural aneurysmal perforation, whereas stent-supported bleeding is a mixture of subarachnoid and parenchymal hemorrhage.
A relatively large percentage of patients (22%) were treated in the setting of acute or recent subarachnoid hemorrhage, a factor well known to increase both overall, 41, 44 and particularly hemorrhagic [44] [45] [46] treatment risk. Because no subset complication analysis with respect to aneurysm rupture status was feasible as a result of the tendency of most publications to report combined statistics, it is unclear to what extent these "ruptured" patients have contributed to overall complication incidence. However, as suggested by other studies of aneurysm coiling, 47 the rupture disposition of an aneurysm has been shown to be highly correlated with treatment-related complications, and it may be reasonable to assume that a similar correlation exists for stent-assisted coiling. Stent-related technical issues were an important focus of attention in our analysis. Again, we found that categorization of stent complications was limited both by range and prevalence of potential issues and by variability in their description. Eventually, we decided to subdivide stent-related technical issues into categories of 'delivery failure' and 'other', with 'other' containing any untoward technical occurrence among patients in whom a stent was deployed.
The learning curve analysis, we believe, clearly demonstrates the significance of operator experience in the overall success of treatment. To some unquantifiable extent however, this experience factor is probably diluted by concurrent evolution in stent technology.
The success of aneurysm occlusion, both initial and followup, is a particularly difficult parameter to analyze and interpret, and is subject to heterogeneity in grading practices and operator bias. Furthermore, its comparison to similar metrics of coiling series is suspect in that the target aneurysm populations are unlikely to be similar (with stent-assisted coiling typically being used for more complex aneurysms). The overall number of complete occlusions represents an aggregate of cases with varied aneurysm size and morphology. Therefore, we feel that direct comparison of occlusion rates between stent-assisted and traditional coiling is apt to be misleading unless various morphologic parameters can be controlled. Such an analysis is beyond the capability of a retrospective literature review. The overall numbers, particularly regarding incidence of retreatment and progressive thrombosis, can nevertheless be useful in terms of patient counseling and procedural planning. Although the occlusion "cure" rate at median 6-month follow-up is 61%, reflecting an aggregate progressive thrombosis relative to initial angiographic occlusion rate of 45%, the long-term angiographic outcome is somewhat discouraging, particularly considering the relatively high prevalence of "small" aneurysms within our literature pool. Further characterization of occlusion rates with respect to relevant aneurysm complexity parameters could not be accomplished due to incomplete and heterogeneous reporting practices, though there is clear documentation from larger individual series 16 that increasing aneurysm complexity is associated with significantly higher treatment failure rates. In reviewing the aneurysm demographics, it became evident that stent-assisted coiling, paradoxically, is being applied predominantly for the treatment of small aneurysms that constitute approximately 63% of the overall cohort. Although this may reflect use of the technique in treating small aneurysms with unfavorable dome-to-neck ratios, it also may suggest expanded use of the technique beyond its initial indication to include aneurysms amenable to direct or balloon-assisted coiling. This possible evolution in the use of stent-assisted coiling is perhaps driven by a perception that stent placement, in some way, improves the long-term angiographic outcome compared with coiling alone. This raises a potentially important, and as yet incompletely answered, question related to the necessity of aneurysm occlusion in realizing the goals of endovascular aneurysm treatment: the prevention of bleeding and rebleeding and relief of symptomatic mass effect. 1, 48, 49 In this regard, the prevalence of incomplete occlusion in our cohort is somewhat disappointing, especially considering the additional technical complexity of stent-assisted coiling.
The possibilities of delayed in-stent stenosis and occlusion have assumed greater importance as the adjunctive use of stents has gained wider acceptance in the treatment of relatively "uncomplicated" aneurysms, a trend suggested by the percentage of small-sized aneurysms treated in our study cohort. In the relatively short follow-up period (6 months median) we found a rather small incidence of stenosis reported. Nevertheless, ϳ1% of stented vessels seem to be occluded at follow-up. Most stenoses and occlusions appear to be clinically silent-in our analysis only 4 of 24 (17%) stenoses and 1 of 4 occlusions were symptomatic. Although there is some evidence to suggest that both stenosis and occlusion occur relatively early after stent implantation 5, 9, 50 and that some untreated stenoses appear to spontaneously resolve on continued follow-up, 9,50 long-term (3-5-year range) angiographic data are required to better understand the natural history of this process. Clinical follow-up data, showing a 3% risk of TIA or stroke in the stent-coiled territory, also merit more rigorous long-term study.
Conclusions
We have compiled the largest to date literature survey of stentsupported aneurysm coiling. Although the reporting of clinical and angiographic follow-up is heterogeneous, the results presented here suggest that stents can be used adjunctively with endosaccular coiling by well-trained operators at the potential price of somewhat increased risks of thromboembolism and parenchymal hemorrhage. The incidence of stentrelated difficulties seems to decrease significantly as operators gain experience with these devices. Ultimately, it seems that approximately 61% of aneurysms, many displaying unfavorable anatomic characteristics and less amenable to other treatment modalities, can be occluded with stent-assisted coiling. In the future, next-generation endoluminal devices will probably further expand the scope and effectiveness of endovascular aneurysm treatment.
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